{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:05:23Z","timestamp":1787695523858,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.surg.2025.109872","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T04:49:01Z","timestamp":1765428541000},"page":"109872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-patient-data meta-analysis and trial sequential analysis of randomized controlled trials"],"prefix":"10.1016","volume":"193","author":[{"given":"Hwee Leong","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren Weiquan","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennedy Yao Yi","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suat Ying","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joycelyn Jie Xin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Wai-Meng","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Kim Poh","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5006-4174","authenticated-orcid":false,"given":"Ye Xin","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2025.109872_bib1","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.surg.2025.109872_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.surg.2025.109872_bib4","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1200\/JCO.2017.72.4948","article-title":"Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline update","volume":"35","author":"Khorana","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2025.109872_bib5","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1245\/s10434-014-3722-6","article-title":"The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma","volume":"21","author":"Wu","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2025.109872_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.hpb.2019.06.019","article-title":"The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis","volume":"22","author":"Mackay","year":"2020","journal-title":"HPB"},{"key":"10.1016\/j.surg.2025.109872_bib7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","article-title":"Neoadjuvant therapy for pancreatic cancer","volume":"20","author":"Springfeld","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.surg.2025.109872_bib8","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.pan.2018.09.012","article-title":"Diagnosis and management of pancreatic cancer in adults: a summary of guidelines from the UK National Institute for Health and Care Excellence","volume":"18","author":"O'reilly","year":"2018","journal-title":"Pancreatology"},{"key":"10.1016\/j.surg.2025.109872_bib9","article-title":"Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Junior","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.surg.2025.109872_bib10","first-page":"1","article-title":"Clinical outcomes of neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: systematic review and meta-analysis of latest randomized controlled trials","volume":"32","author":"Chan","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2025.109872_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrae172","article-title":"Neoadjuvant treatment versus upfront surgery in borderline resectable and resectable pancreatic ductal adenocarcinoma: meta-analysis","volume":"9","author":"Dickerson","year":"2025","journal-title":"BJS open"},{"key":"10.1016\/j.surg.2025.109872_bib12","article-title":"Neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer: results of the randomized phase II\/III Prep-02\/JSAP05 Trial","author":"Unno","year":"2025","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2025.109872_bib13","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO-24-01378","article-title":"Neoadjuvant FOLF (IRIN) OX chemotherapy for resectable pancreatic adenocarcinoma: a multicenter randomized noncomparative phase II trial (PANACHE01 FRENCH08 PRODIGE48 study)","volume":"43","author":"Schwarz","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2025.109872_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"10.1016\/j.surg.2025.109872_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.surg.2025.109872_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.surg.2025.109872_bib17","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.surg.2025.109872_bib18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.surg.2025.109872_bib19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.surg.2025.109872_bib20","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.surg.2025.109872_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2023.05.010","article-title":"The development methods of official GRADE articles and requirements for claiming the use of GRADE\u2013A statement by the GRADE guidance group","volume":"159","author":"Sch\u00fcnemann","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.surg.2025.109872_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2016.01.032","article-title":"GRADE guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health","volume":"76","author":"Sch\u00fcnemann","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.surg.2025.109872_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.surg.2025.109872_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00066-014-0737-7","article-title":"Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial","volume":"191","author":"Golcher","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.surg.2025.109872_bib25","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s11605-015-2890-4","article-title":"Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets","volume":"19","author":"Casadei","year":"2015","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.surg.2025.109872_bib26","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/SLA.0000000000005126","article-title":"Neoadjuvant therapy for resectable pancreatic cancer: a new standard of care. Pooled data from 3 randomized controlled trials","volume":"274","author":"Birrer","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2025.109872_bib27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","article-title":"Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2\u20133 trial","volume":"3","author":"Reni","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.surg.2025.109872_bib28","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2025.109872_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","article-title":"Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)\u2014A randomized phase II trial of the AIO pancreatic cancer group","volume":"34","author":"Seufferlein","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.surg.2025.109872_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfrownt surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.surg.2025.109872_bib31","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.ejso.2022.04.011","article-title":"Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer","volume":"48","author":"Cucchetti","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.surg.2025.109872_bib32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.pan.2025.05.008","article-title":"SEER-Based evaluation of lymph node yield as a prognostic indicator of cancer-specific survival in nonmetastatic pancreatic ductal adenocarcinoma","volume":"25","author":"Tan","year":"2025","journal-title":"Pancreatology"},{"key":"10.1016\/j.surg.2025.109872_bib33","doi-asserted-by":"crossref","first-page":"543","DOI":"10.5858\/arpa.2020-0032-RA","article-title":"The 8th edition American joint committee on cancer staging for hepato-pancreato-biliary cancer: a review and update","volume":"145","author":"Liao","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.surg.2025.109872_bib34","first-page":"93","article-title":"et al.The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.surg.2025.109872_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","article-title":"Optimizing the outcomes of pancreatic cancer surgery","volume":"16","author":"Strobel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.surg.2025.109872_bib36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"10.1016\/j.surg.2025.109872_bib37","first-page":"1","article-title":"The landmark series: neoadjuvant therapy for resectable pancreatic cancer","volume":"32","author":"Cardell","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2025.109872_bib38","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1245\/s10434-013-2882-0","article-title":"The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma","volume":"20","author":"Abbott","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2025.109872_bib39","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1200\/OP.22.00536","article-title":"Neoadjuvant treatment versus upfront surgery in resectable pancreatic cancer: a cost-effectiveness analysis","volume":"19","author":"Arjani","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.surg.2025.109872_bib40","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jamcollsurg.2007.12.020","article-title":"Borderline resectable pancreatic cancer: the importance of this emerging stage of disease","volume":"206","author":"Katz","year":"2008","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.surg.2025.109872_bib41","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamasurg.2024.2485","article-title":"Futility of Up-Front resection for anatomically resectable pancreatic cancer","volume":"159","author":"Crippa","year":"2024","journal-title":"JAMA Surg"},{"key":"10.1016\/j.surg.2025.109872_bib42","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.surg.2020.02.013","article-title":"A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma","volume":"168","author":"Guo","year":"2020","journal-title":"Surgery"},{"key":"10.1016\/j.surg.2025.109872_bib43","doi-asserted-by":"crossref","first-page":"e914","DOI":"10.1097\/SLA.0000000000004845","article-title":"A pretreatment prognostic Score to stratify survival in pancreatic cancer","volume":"276","author":"Hank","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2025.109872_bib44","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1097\/MPA.0000000000002485","article-title":"Efficacy of neoadjuvant therapy for resectable pancreatic cancer might be limited to biologically borderline resectable cases","volume":"54","author":"Kato","year":"2025","journal-title":"Pancreas"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003960602500724X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003960602500724X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T22:12:05Z","timestamp":1776377525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003960602500724X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"alternative-id":["S003960602500724X"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2025.109872","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-patient-data meta-analysis and trial sequential analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2025.109872","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109872"}}